- AstraZeneca said European regulators had delivered a positive opinion on the cardiovascular outcomes of its type-2 diabetes treatment that would see even more people benefit from the drug.

The European Medicines Agency's Committee for Medicinal Products for Human Use had recommended a change to the European marketing authorisation for Forxiga (dapagliflozin) in patients with type-2 diabetes to include cardiovascular outcomes data from the Phase III DECLARE-TIMI 58 trial.

The DECLARE-TIMI 58 trial confirmed the well-established safety profile of the company's type-2 diabetes drug Forxiga, the company said. The trial showed no imbalance with Forxiga versus placebo in amputations, fractures, bladder cancer or Fournier's gangrene.

'We are pleased with this positive opinion for the cardiovascular outcomes and renal data for Forxiga and this recommendation acknowledges that even more people with type-2 diabetes could benefit from this medicine,' the company said

At 8:17am: [LON:AZN] AstraZeneca PLC share price was +3p at 6441p

Story provided by